SCHEMBL1639294

SCHEMBL1639294

Nc1nc(-c2cccc(NC(=O)c3c(F)cccc3F)c2)c(-c2ccnc(Cl)n2)s1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 3/20 0.49
PKMYT1 Q99640 1/20 0.44
MAPT P10636 2/20 0.44
TP53 P04637 1/20 0.44
TGFBR1 P36897 1/20 0.43
SLC2A1 P11166 1/20 0.42
IGF1R P08069 7/20 0.42
EGFR P00533 6/20 0.42
ERBB2 P04626 6/20 0.42
AURKA O14965 1/20 0.42
PRKD3 O94806 1/20 0.42
MAP4K4 O95819 1/20 0.42
CHEK2 O96017 1/20 0.42
NTRK1 P04629 1/20 0.42
INSR P06213 1/20 0.42
LCK P06239 1/20 0.42
FYN P06241 1/20 0.42
CSF1R P07333 1/20 0.42
LYN P07948 1/20 0.42
RET P07949 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1640498 0.90 BRAF (0.49) BRAFPKMYT1MAPTTP53SLC2A1
SCHEMBL1641904 0.89 BRAF (0.51) BRAFPKMYT1MAPTTP53SLC2A1
SCHEMBL1640608 0.88 BRAF (0.47) BRAFMAPTTGFBR1EGFRERBB2
SCHEMBL1640575 0.88 BRAF (0.43) BRAFMAPTTGFBR1RORBABL1
SCHEMBL1641055 0.88 FBP1 (0.43) BRAFTP53TGFBR1LMNASMN1; SMN2
SCHEMBL1641468 0.87 BRAF (0.48) BRAFPKMYT1MAPTTP53SLC2A1
SCHEMBL1641081 0.87 BRAF (0.49) BRAFPKMYT1MAPTTP53SLC2A1
SCHEMBL12726212 0.87 BRAF (0.58) BRAFPKMYT1SLC2A1IGF1REGFR
SCHEMBL1642030 0.86 BRAF (0.64) BRAFPKMYT1MAPTTP53IGF1R
SCHEMBL1640568 0.86 BRAF (0.49) BRAFPKMYT1MAPTTP53SLC2A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110098296-A1 Thiazole And Oxazole Kinase Inhibitors GLAXOSMITHKLINE LLC 2011-04-28 US disclosed
US-20110098296-A1 Thiazole And Oxazole Kinase Inhibitors GLAXOSMITHKLINE LLC 2011-04-28 US disclosed
US-20110098296-A1 Thiazole And Oxazole Kinase Inhibitors GLAXOSMITHKLINE LLC 2011-04-28 US disclosed
EP-2231625-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS GlaxoSmithKline LLC (US) 2010-09-29 EP disclosed
WO-2009076140-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-06-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098296-A1 Thiazole And Oxazole Kinase Inhibitors PDXK, MAP3K1, MAP4K2 BRAF 151/4885PKMYT1 485/4885MAPT 1402/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.